Mereo BioPharma Group plc (MAH0) - Total Assets
Based on the latest financial reports, Mereo BioPharma Group plc (MAH0) holds total assets worth €53.60 Million EUR (≈ $62.67 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See MAH0 book value for net asset value and shareholders' equity analysis.
Mereo BioPharma Group plc - Total Assets Trend (2016–2024)
This chart illustrates how Mereo BioPharma Group plc's total assets have evolved over time, based on quarterly financial data.
Mereo BioPharma Group plc - Asset Composition Analysis
Current Asset Composition (December 2024)
Mereo BioPharma Group plc's total assets of €53.60 Million consist of 97.9% current assets and 2.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 91.4% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Mereo BioPharma Group plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Mereo BioPharma Group plc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mereo BioPharma Group plc's current assets represent 97.9% of total assets in 2024, an increase from 70.1% in 2016.
- Cash Position: Cash and equivalents constituted 91.4% of total assets in 2024, up from 61.8% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 29.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Mereo BioPharma Group plc Competitors by Total Assets
Key competitors of Mereo BioPharma Group plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $1.30 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥38.02 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.48 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Mereo BioPharma Group plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.71 | 6.10 | 3.47 |
| Quick Ratio | 8.71 | 6.10 | 3.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €46.39 Million | €72.52 Million | €21.16 Million |
Mereo BioPharma Group plc - Advanced Valuation Insights
This section examines the relationship between Mereo BioPharma Group plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.24 |
| Latest Market Cap to Assets Ratio | 0.53 |
| Asset Growth Rate (YoY) | 14.9% |
| Total Assets | €76.39 Million |
| Market Capitalization | $40.19 Million USD |
Valuation Analysis
Below Book Valuation: The market values Mereo BioPharma Group plc's assets below their book value (0.53x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Mereo BioPharma Group plc's assets grew by 14.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Mereo BioPharma Group plc (2016–2024)
The table below shows the annual total assets of Mereo BioPharma Group plc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €76.39 Million ≈ $89.31 Million |
+14.87% |
| 2023-12-31 | €66.50 Million ≈ $77.74 Million |
-24.50% |
| 2022-12-31 | €88.08 Million ≈ $102.97 Million |
-30.33% |
| 2021-12-31 | €126.42 Million ≈ $147.79 Million |
+100.83% |
| 2020-12-31 | €62.95 Million ≈ $73.59 Million |
-27.19% |
| 2019-12-31 | €86.45 Million ≈ $101.07 Million |
+28.50% |
| 2018-12-31 | €67.28 Million ≈ $78.65 Million |
-30.16% |
| 2017-12-31 | €96.34 Million ≈ $112.63 Million |
+11.03% |
| 2016-12-31 | €86.76 Million ≈ $101.44 Million |
-- |
About Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navi… Read more